Drug class profile · refreshed daily from federal data

Histamine-2 Receptor Antagonist

6 molecules in this class, $266.7M combined CY2024 Part D spend across 21.5M claims. Class-level guide below for benefits decision-makers: where the money lives, where the savings live.

Last updated 15 Oct 2026

NADAC: weekly (every Wed)Part D Formulary: quarterlyPart D Spend: annualOrange Book: weeklyShortages: daily

Class summary at a glance.

Every drug in the Histamine-2 Receptor Antagonist class tracked across NADAC, Part D Formulary, Part D Spending, FDA Orange Book, and shortage data. Ranked below by CY24 Part D spend. Click any molecule for the full drug profile.

Molecules in class: 6tracked in Part D
CY24 Part D spend: $266.7Mcombined across class
Total Rx claims: 21.5M7.2M unique beneficiaries
Generic mfrs (active): 52across all molecules

Every drug in this class, ranked by Part D spend.

CY2024 dataCMS Part D Spending Dashboard

Famotidine

Brand: Pepcid · 21.4M Part D claims (CY24) · 7.1M beneficiaries · First FDA approval: 2001-03-15

34 generic mfrs 0 plans require PA

Low NADAC$0.029

→

Avg plan cost$0.058

Part D spend $257.1M 2× spread, current vs floor

Class share

96%

of class CY24 spend

View profile →

Cimetidine

151K Part D claims (CY24) · 46K beneficiaries · First FDA approval: 1994-05-17

7 generic mfrs 0 plans require PA

Low NADAC$0.204

→

Avg plan cost$0.389

Part D spend $9.0M 2× spread, current vs floor

Class share

of class CY24 spend

View profile →

Nizatidine

7K Part D claims (CY24) · 2K beneficiaries · First FDA approval: 2002-07-09

3 generic mfrs 0 plans require PA

Low NADAC$0.799

→

Avg plan cost$0.802

Part D spend $670367 1× spread, current vs floor

Class share

of class CY24 spend

View profile →

Ibuprofen Famotidine

— Part D claims (CY24) · First FDA approval: 2025-09-18

Brand-only (no generics)

Low NADAC—

→

Avg plan cost—

Part D spend —

Class share

of class CY24 spend

View profile →

Ibuprofen and Famotidine

— Part D claims (CY24) · First FDA approval: 2021-08-04

4 generic mfrs 6 plans require PA

Low NADAC$0.714

→

Avg plan cost$0.714

Part D spend — 1× spread, current vs floor

Class share

of class CY24 spend

View profile →

Ranitidine

— Part D claims (CY24) · First FDA approval: 2001-01-12

4 generic mfrs 0 plans require PA

Low NADAC—

→

Avg plan cost—

Part D spend —

Class share

of class CY24 spend

View profile →

Class summary at a glance.

Every drug in this class, ranked by Part D spend.

Related questions.